Navigation Links
Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
Date:5/8/2013

ST. LOUIS, MO May 8, 2013 Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. These results are now published online in the Journal of Clinical Oncology. A copy of the results can be obtained here, together with a commentary by Michael Maitland, MD, Ph.D., assistant professor of Medicine in the Section of Hematology/Oncology, and associate director, Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago Medicine, Chicago, IL.

Researchers estimated several tumor-size response metrics using longitudinal tumor-size models and data from two Phase III clinical trials, which compared bevacizumab with chemotherapy versus chemotherapy alone as first-line therapy for colorectal cancer. Trial participants included 923 Western and 203 Chinese patients. Baseline prognostic factors and the tumor-size metric estimates were assessed in multivariate models to predict overall survival. Multiple simulations of the Phase III studies were used to test the models' predictive capabilities.

Time to tumor growth proved to be the best metric for predicting overall survival. The proposed model worked equally well when predicting overall survival rates for the Western and Chinese patients and as such could be used to support drug development decisions in either population.

Ren Bruno, Ph.D., managing director of Certara's Pharsight Consulting Services Europe, and senior author of the paper, said: "This approach of combining modeling with longitudinal tumor-size data may contribute to improved design and analysis of more informative early-stage clinical studies (Phase Ib, II). It could also enable researchers to select the most promising treatments and reduce the high attrition rate in Phase III oncology studies."

Robert Powell, PharmD, former senior advisor at Roche China, and co-author of the paper, added: "It is important to know whether patients in a new market (e.g., China, India, Brazil) will be similar to patients in the original US or EU New Drug Application (NDA). While pharmaceutical companies usually assume patients from different regions are the same, there is emerging evidence that they might be different with regard to efficacy, safety and dose response. This type of analysis helps better define Chinese colon cancer response relative to Western patients. Roche performed this combined Chinese and US NDA study analysis to learn whether Chinese patients responded similarly to Western patients so they can use this information to plan future trials. Likewise knowing these results will be important to local regulatory agencies such as the China Food and Drug Administration in this case."


'/>"/>

Contact: Lisa Osborne
lisa@ranahealth.com
206-992-5245
Rana Healthcare Solutions LLC
Source:Eurekalert

Related medicine news :

1. Improved Stem Cell Line May Avoid Tumor Risk: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Dental X-Rays May Be Linked to Benign Brain Tumors
4. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
5. Brain Tumor Vaccine Shows Promise in Early Trial
6. Kidney Cancer Patients Fare Better With Tumor Removal Only
7. IBN discovers human neural stem cells with tumor targeting ability
8. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
9. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
10. New surgical technique for removing inoperable tumors of the abdomen
11. Combination of 2 drugs reverses liver tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2019)... ... 2019 , ... Edens Garden launches 7 new, natural deodorant aromas ... 100% pure essential oils and non-toxic ingredients to keep you fresh all day. Finally, ... product release all-natural but baking soda- and aluminum-free, making this deodorant a must for ...
(Date:4/18/2019)... ... April 18, 2019 , ... BNCT is a powerful alternative ... to cancer cells while sparing surrounding healthy tissue. NTI’s unique and patented neutron ... ground up for high reliability and ease of maintenance, NTI’s platform can enable ...
(Date:4/18/2019)... BEVERLY HILLS, Calif. (PRWEB) , ... April 18, ... ... at an upscale dental practice in Beverly Hills that offers a full menu ... his superior cosmetic treatments and sought-after expertise in biomimetic dentistry, which relies on ...
(Date:4/18/2019)... ... April 18, 2019 , ... As cannabis ... Cannabis Industry Report . The study—which considers consumers’ perceptions of, attitudes about, and ... manufacturing, offering insight into what kinds of products consumers want to see. , ...
(Date:4/17/2019)... ... April 17, 2019 , ... Ramneek ... Korean company located in Gwangju, Korea, and has highly evaluated and confirmed iRINGER’s ... two companies were in discussion of a potential partnership since then. ...
Breaking Medicine News(10 mins):
(Date:4/19/2019)... ... April 19, 2019 , ... Dr. Draion Burch (Dr. Drai) CEO & ... their medical degree outside of the hospital, has been accepted into Forbes Coaches Council, ... and selected by a review committee based on the depth and diversity of his ...
(Date:4/19/2019)... ... April 19, 2019 , ... ... is now certified in the LANAP and LAPIP protocols. Dr. Pumphrey is on ... with favorable and predictable results to save their teeth and implants and help ...
(Date:4/19/2019)... ... ... CBD Hacker , the definitive guide to the CBD industry, has ... the best sales from brands that CBD Hacker’s team has thoroughly reviewed and vetted ... items. And CBD Hacker has also partnered with several leading brands to share exclusive ...
Breaking Medicine Technology: